Expanded Access Data Can Support Approval Decisions, US FDA Says

Pink Sheet featured an article authored by Kate Rawson which highlights important takeaways from our public meeting, Leveraging Real-World Treatment Experience from Expanded Access Protocols on November 19, 2018 at the FDA White Oak Campus. Find the summary and access to the article below.

Executive Summary

Formal reg not needed, according to agency; officials agree that regulatory flexibility is best way to offer sponsors advice, saying data collected during compassionate use can be helpful in guiding regulatory decisions.

Reagan-Udall Foundation for the FDA Announces Appointment of Three New Board Members

The Reagan-Udall Foundation for the Food and Drug Administration expands its leadership with the appointment of three new Board members: Andrew C. von Eschenbach, M.D., former FDA Commissioner; Edward John Allera JD, pharmacist and attorney with expertise in FDA regulation and biotechnology; and, Lynne Zydowsky, Ph.D., a biotechnology and life science executive.

Read the full press release here.

2018 Innovations in Regulatory Science Awards Dinner

The Reagan-Udall Foundation for the FDA honored two longtime U.S. Food and Drug Administration leaders and an independent public-private partnership as the 2018 recipients of the Innovations in Regulatory Science Awards.

This year’s Innovations in Regulatory Science Awards Dinner, a premier event launched in 2017, brought together leaders in academia, advocacy, industry and government to celebrate the achievements and continued contributions of outstanding regulatory science leaders.